Mark Verrill - Concepedia

Author

Mark Verrill

Also Known As

J. Beith, M Verrill, M W Verrill, M. VERRILL, M. Verrill, M. W. Verrill, M.W Verrill, M.W. Verrill, Mark Verrill, Mark W Verrill

130

Publications

3.9K

Citations

H-Index

Concepts

All Affiliations

Freeman Hospital Newcastle University Institute of Cancer Research Beatson West of Scotland Cancer Centre University College London

About

Mark Verrill is an author at Freeman Hospital specializing in medicine, oncology, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	20	781
2	Health Sciences	5	5	258
3	Immunology	2	2	34
4	Social Sciences	1	1	32
5	Hepatology	1	1	28

Mark Verrill

Publications

2.4K

Citations

H-Index

Page 1

	Year	Citations
Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study Sandra M. Swain, Michael S. Ewer, Giuseppe Viale, Annals of Oncology	2017	237
Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring Anna Jones, Malcolm Barlow, Peter Barrett‐Lee, British Journal of Cancer	2009	215
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial Peter Barrett‐Lee, Lindsay Johnson, David Cameron, The Lancet Breast OncologyOncologyPhase IiiClinical TrialsAdjuvant Chemotherapy	2009	188
Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide Johanne Bray, J Sludden, Martin J. Griffin, British Journal of Cancer	2010	179
Phase I Clinical and Pharmacokinetic Study of Pemetrexed and Carboplatin in Patients With Malignant Pleural Mesothelioma Andy Hughes, Paula Calvert, Ashraf Azzabi, Journal of Clinical Oncology	2002	148
Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) Thomas Bachelot, Eva Ciruelos, Fabio Puglisi, Annals of Oncology Metastatic Breast CancerBreast OncologyMedicinePathologyPreliminary Safety	2019	111
Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer José Baselga, Milvia Zambetti, Antonio Llombart‐Cussac, Journal of Clinical Oncology	2008	110
A Phase I and Pharmacokinetic Study of Paclitaxel Poliglumex (XYOTAX), Investigating Both 3-Weekly and 2-Weekly Schedules Alan V. Boddy, E. Ruth Plummer, R Todd, Clinical Cancer Research	2005	106
Ewing's sarcoma and primitive neuroectodermal tumor in adults: are they different from Ewing's sarcoma and primitive neuroectodermal tumor in children? Mark Verrill, Ian Judson, Clive Harmer, Journal of Clinical Oncology	1997	101
An investigation into the psychometric properties of the Hospital Anxiety and Depression Scale in patients with breast cancer Jacqui Rodgers, Colin R. Martin, Rachel Morse, Health and Quality of Life Outcomes	2005	91

Page 1